Wed, September 5, 2012
Tue, September 4, 2012
Mon, September 3, 2012
Sun, September 2, 2012
Sat, September 1, 2012
Fri, August 31, 2012
Thu, August 30, 2012
Wed, August 29, 2012
Tue, August 28, 2012
Mon, August 27, 2012
Sun, August 26, 2012
Sat, August 25, 2012
Fri, August 24, 2012
Thu, August 23, 2012
Wed, August 22, 2012
[ Wed, Aug 22nd 2012 ] - Market Wire
Inergetics Shareholder Update

Exelixis Provides Update on ODAC Panel for Cabozantinib


//health-fitness.news-articles.net/content/2012/ .. vides-update-on-odac-panel-for-cabozantinib.html
Published in Health and Fitness on Wednesday, August 29th 2012 at 14:18 GMT by Market Wire   Print publication without navigation


SOUTH SAN FRANCISCO, Calif.--([ ])--Exelixis, Inc. (NASDAQ: EXEL) today was notified by the Food and Drug Administration (the aFDAa) that the Companyas new drug application (aNDAa) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer has been removed from the agenda for the November 8 and November 9, 2012 meeting of the FDAas Oncologic Drugs Advisory Committee (aODACa). As a result, the Company does not anticipate a discussion of the NDA by ODAC.The previously announced Prescription Drug User Fee Act (PDUFA) action date remains November29, 2012.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at [ http://www.exelixis.com ].


Publication Contributing Sources